Zaldivar's disease (familial hypercholesterolemia type IIa) - Symptoms, Causes, Treatment & Prevention

📅 Updated: May 2026 ⏱️ 6 min read ✅ Medically reviewed
Zaldivar’s Disease (Familial Hypercholesterolemia Type IIa) – Complete Medical Guide

Zaldivar’s Disease (Familial Hypercholesterolemia Type IIa)

Overview

Zaldivar’s disease is the eponym sometimes used in older literature for familial hypercholesterolemia type IIa (FH‑IIa), an inherited disorder that dramatically elevates low‑density lipoprotein cholesterol (LDL‑C) from birth. The condition results from mutations that impair the LDL‑receptor pathway, preventing normal clearance of LDL particles from the bloodstream.

  • Who it affects: Both males and females; autosomal‑dominant inheritance means a child has a 50 % chance of inheriting the mutation from an affected parent.
  • Prevalence: Heterozygous FH (one defective gene) occurs in about 1 in 250–300 people worldwide, making it one of the most common monogenic disorders. Homozygous FH (two defective genes) is far rarer, estimated at 1 in 300,000–500,000, but carries a severe early‑onset risk of cardiovascular disease.1,2
  • Why the name? The “Zaldivar” designation originated from a 1970s case series describing a family with severe hypercholesterolemia; today the condition is almost always referenced as familial hypercholesterolemia (FH) or FH‑IIa.

Symptoms

Patients with FH often appear physically normal in childhood, but characteristic signs may develop over time:

Cutaneous & Tendon Findings

  • Xanthomas: Yellowish, cholesterol‑laden nodules on tendons (especially the Achilles and extensor tendons of the hands), elbows, knees, and buttocks.
  • Xanthelasma: Soft, flat, yellow plaques on the eyelids; more common in adults.
  • Corneal arcus: A gray‑white ring at the peripheral cornea, often seen before age 45 in FH patients.

Cardiovascular Symptoms

  • Chest pain or angina (often atypical in younger patients).
  • Shortness of breath on exertion.
  • Palpitations or syncope, especially if coronary artery disease (CAD) is advanced.

Other Possible Findings

  • Early‑onset peripheral arterial disease (claudication).
  • Stroke or transient ischemic attack (TIA) in younger adults.
  • Fatigue, decreased exercise tolerance, or “heart‑filled” feeling without obvious chest pain.

In homozygous FH, symptoms can manifest in the first decade of life, including severe aortic valve disease, premature myocardial infarction (MI), and extensive aortic calcification.

Causes and Risk Factors

FH‑IIa is caused by genetic defects that reduce the number or function of LDL receptors on hepatocytes.

Genetic Causes

  • LDLR gene mutations – the most common cause (≈85 % of heterozygous FH).
  • APOB gene mutations – affect the ligand that binds LDL receptors (≈5 % of cases).
  • PCSK9 gain‑of‑function mutations – increase LDL‑R degradation (≈2–3 %).
  • Rarely, mutations in LDLRAP1 cause an autosomal‑recessive form.

Non‑Genetic Risk Modifiers

  • Unhealthy diet high in saturated fats and trans‑fatty acids.
  • Obesity, metabolic syndrome, and type 2 diabetes.
  • Smoking, sedentary lifestyle, and chronic stress.
  • Co‑existing genetic variations (polygenic risk scores) that can amplify LDL‑C levels.

Who Is at Highest Risk?

  • Individuals with a first‑degree relative diagnosed with FH.
  • Patients with tendon xanthomas or early‑onset coronary artery disease (<45 y for men, <55 y for women).
  • Those of South African, Dutch, or Lebanese ancestry, where founder mutations raise FH prevalence.

Diagnosis

Because FH is often silent until a cardiovascular event occurs, proactive screening is essential.

Clinical Criteria

  • Simon Broome criteria (UK) – combines LDL‑C levels, physical signs, and family history.
  • Dutch Lipid Clinic Network (DLCN) score – assigns points for cholesterol level, xanthomas, family history, and genetic testing; ≥6 points = “definite FH”.

Laboratory Tests

  • Lipid panel:
    • LDL‑C > 190 mg/dL (≈4.9 mmol/L) in adults without secondary causes suggests heterozygous FH.
    • LDL‑C > 500 mg/dL (≈13 mmol/L) in children or any age points to homozygous FH.
  • Triglycerides are usually normal (<150 mg/dL).
  • Comprehensive metabolic panel to rule out secondary hyperlipidemia (hypothyroidism, renal disease, etc.).

Genetic Testing

Sequencing of LDLR, APOB, and PCSK9 confirms the diagnosis in 70‑80 % of clinically suspected cases. Testing is especially useful for cascade screening of relatives.

Imaging & Functional Tests

  • Coronary artery calcium (CAC) scoring: Detects subclinical atherosclerosis.
  • Echocardiography & carotid Doppler: Evaluates valve disease and carotid plaque.
  • Stress testing or coronary CT angiography for patients with intermediate symptoms.

Treatment Options

Therapy aims to lower LDL‑C as early and as aggressively as possible to prevent premature atherosclerotic disease.

First‑Line Lipid‑Lowering Medications

  • Statins (HMG‑CoA reductase inhibitors) – rosuvastatin, atorvastatin, pitavastatin. Target ≥50 % reduction in LDL‑C.
  • Ezetimibe – blocks intestinal cholesterol absorption; adds ~15‑20 % LDL‑C reduction when combined with statins.

Second‑Line & Adjunctive Therapies

  • PCSK9 inhibitors (alirocumab, evolocumab) – monoclonal antibodies that reduce LDL‑C by 50‑60 % and are now first‑line for homozygous FH or statin‑intolerant patients.3
  • Bile‑acid sequestrants (cholestyramine, colesevelam) – modest 10‑15 % LDL‑C drop.
  • Lomitapide – microsomal triglyceride transfer protein (MTP) inhibitor; reduces LDL‑C 30‑50 % but carries GI side effects and hepatic fat accumulation risk.
  • Inclisiran – small interfering RNA that lowers PCSK9 synthesis; dosing every 6 months, 40‑45 % LDL‑C reduction.

Procedural Interventions

  • Lipoprotein apheresis – extracorporeal removal of LDL‑C; indicated for homozygous FH or severe heterozygous FH not controlled by medication.
  • Coronary revascularization (PCI or CABG) for obstructive CAD.
  • Valve replacement surgery for severe aortic stenosis caused by cholesterol deposits.

Lifestyle Modifications (Foundational)

  • Heart‑healthy diet: Emphasize fruits, vegetables, whole grains, legumes, nuts, fatty fish; limit saturated fat <7 % of total calories and eliminate trans fats.
  • Physical activity: ≥150 minutes/week of moderate aerobic exercise (e.g., brisk walking) plus resistance training 2 days/week.
  • Weight management: Maintain BMI 18.5‑24.9 kg/m².
  • Smoking cessation: Use nicotine replacement, counseling, or prescription meds.
  • Alcohol moderation – ≤2 drinks/day for men, ≤1 for women.

Living with Zaldivar’s disease (familial hypercholesterolemia type IIa)

Management is a lifelong partnership between the patient, family, and healthcare team.

Daily Management Tips

  • Medication adherence: Use pill organizers, set alarms, and keep a medication list.
  • Regular labs: Lipid panel every 3‑6 months after medication changes; annually once stable.
  • Track your diet: Apps like MyFitnessPal can help stay within saturated‑fat limits.
  • Family screening: Offer cascade genetic testing to first‑degree relatives; early detection saves lives.
  • Vaccinations: Flu and COVID‑19 vaccines reduce infection‑related inflammatory spikes that can worsen lipid levels.
  • Stress reduction: Mindfulness, yoga, or counseling can indirectly improve heart health.

Psychosocial Support

Living with a hereditary condition can cause anxiety or guilt. Consider:

  • Support groups (e.g., FH Foundation, local patient networks).
  • Genetic counseling to discuss inheritance patterns and family planning.
  • Professional mental‑health care if feelings of depression or overwhelm arise.

Prevention

While you cannot alter the genetic defect, you can dramatically reduce cardiovascular risk:

  • Start statin therapy in childhood (as early as 8‑10 years) for children with confirmed FH, per American Academy of Pediatrics guidelines.4
  • Maintain a lipid‑lowering diet and active lifestyle throughout life.
  • Control blood pressure, blood glucose, and body weight.
  • Screen for and treat other modifiable risks (e.g., obstructive sleep apnea).
  • Regularly review medication efficacy and side‑effects with your clinician.

Complications

If untreated or suboptimally managed, FH leads to early and aggressive atherosclerosis.

  • Premature coronary artery disease: Median age of first MI is 45 y in men and 55 y in women with heterozygous FH.5
  • Peripheral arterial disease – claudication, ulceration.
  • Ischemic stroke – especially in young adults.
  • Aortic valve disease – calcific stenosis causing heart failure.
  • Liver dysfunction from high‑dose lipid‑lowering agents (e.g., lomitapide).
  • Psychological impact – chronic disease burden can affect quality of life.

When to Seek Emergency Care

Immediate medical attention is needed if you experience any of the following:
  • Sudden, crushing chest pain or pressure lasting >5 minutes, radiating to the arm, jaw, or back.
  • Shortness of breath, fainting, or severe light‑headedness without an obvious cause.
  • Rapid, weak pulse or sudden loss of consciousness.
  • New, severe headache with visual changes or speech difficulty (possible stroke).
  • Sudden weakness or numbness in a limb, especially on one side of the body.

Call 911 (or your local emergency number) and inform the responders that you have familial hypercholesterolemia.

Sources:
1. World Health Organization. “Familial hypercholesterolaemia.” WHO Fact Sheet, 2022.
2. NICE Guideline NG185. “Familial hypercholesterolaemia: Identification and Management.” 2023.
3. Sabatine MS et al. “Efficacy and safety of PCSK9 inhibitors.” *New England Journal of Medicine*, 2020.
4. American Academy of Pediatrics. “Clinical Report—Lipid Screening and Cardiovascular Health in Children.” 2021.
5. Nordestgaard BG et al. “Familial hypercholesterolaemia is underdiagnosed and undertreated.” *European Heart Journal*, 2019.

⚠️ Medical Disclaimer

Important: The information provided on this page is for general informational purposes only and is not intended as a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition.

If you think you may have a medical emergency, call your doctor, go to the emergency department, or call 911 immediately.

📚 Medical References